(5-(chloromethyl)-2-oxo-1,3-dioxol-4-yl)methyl 1-((2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate

Order (5-(chloromethyl)-2-oxo-1,3-dioxol-4-yl)methyl 1-((2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate product with CAS: 896419-18-4 and speed up your project. This product is also known as (5-(chloromethyl)-2-oxo-1,3-dioxol-4-yl)methyl 1-((2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate; and can be used as a working standard or secondary reference standard. Additional internal validation as per respective FDA regulations/guidelines may require. (5-(chloromethyl)-2-oxo-1,3-dioxol-4-yl)methyl 1-((2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate is used in Olmesartan Medoxofil impurity profiling as per limits and threshold values specified by respective drug legislations, FDA and pharmacopoeial guidelines during commercial production of Olmesartan Medoxofil and its related formulations. Moreover, (5-(chloromethyl)-2-oxo-1,3-dioxol-4-yl)methyl 1-((2′-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1H-imidazole-5-carboxylate is also used in the process of Abbreviated New Drug Application (ANDA) filing to FDA and toxicity study of respective drug formulation.